The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period.
Major Key Players of the Radiopharmaceuticals-Nuclear Medicine Market are:Advanced Accelerator Applications S.A. (France), Bayer AG (Germany), Bracco Imaging S.p.A (Italy), Cardinal Health, Inc. (U.S.), Eli Lilly and Co. (U.S.), GE Healthcare (U.S.), BA Molecular Imaging (Belgium), Jubilant Life Sciences Ltd (India), Lantheus Medical Imaging, Inc. (U.S.), Mallinckrodt plc (Ireland), Navidea Biopharmaceutical (U.S.), Nordion, Inc. (Canada), Siemens Healthineers (Germany)
Read More @ https://www.openpr.com/news/2173191/nuclear-medicine-market-rapidly-growing-dynamics-with
No comments:
Post a Comment